Medable Hires Chief Strategy Officer to Expand Global Partner and Innovation Ecosystem for Decentralized Clinical Trials
Medable Inc., the leading cloud platform for patient-centered drug development, today announced the hiring of Dr. MaryAnne Rizk as Chief Strategy Officer. Rizk is a veteran leader with more than 20 years of experience managing partnerships and ecosystems to accelerate development across technology (Oracle, Medidata), pharmaceutical (Merck), and clinical research organizations (IQVIA).
At Medable, Rizk is charged with expanding the company’s global strategic partnerships and innovation ecosystem together with CROs, medical device companies, software and data partners. The partner initiatives will help Medable advance its vision of human-centered research, enabling remote access to clinical trials across geographies to ensure a diverse representation of people from varied economic and racial backgrounds.
“MaryAnne shares our passion to make clinical research more inclusive, enabling global remote access so anyone anywhere can benefit from the latest therapies,” said Dr. Michelle Longmire, CEO and co-founder of Medable. “No one company can do this alone, and we look forward to building deep and long-lasting partnerships to improve and give voice to the patient experience.”
“We’re excited to pursue a series of distinct and complementary partnerships across a network of service, technology, data and sites that further strengthen Medable impact to serve patients,” said Rizk. “The progress Medable has experienced to date has been remarkable, and we believe that thoughtful and strategic partnerships will empower more ways to advance clinical research. I’m thrilled to join Michelle and the Medable team, who are leading the way with true vision and innovation that can help move the industry forward faster.”
Rizk was recently honored as a PharmaVoice 100 leader, and she has dedicated her career to modernizing the partnership value chain to accelerate transformational outcomes in the life sciences industry. She is an active member of Healthcare Businesswomen’s Association, Prix Galien Foundation Digital Advisory Board, and SCRS Innovation Council. Rizk also serves as an adjunct professor at the Stevens Institute of Technology, where she received her Ph.D., Masters and Bachelor of Engineering degrees.
Medable is an emerging leader in the industry shift to decentralized clinical trials, making trials accessible for everybody everywhere – and enabling effective therapies to reach patients faster. Medable’s software-as-a-service (SaaS) platform has been deployed in more than 60 countries via more than 150 decentralized and hybrid clinical trials. By minimizing the need for in-person site visits, Medable customers have achieved unprecedented results – including 3X faster enrollment, 90 percent retention rates, and 50 percent cost reductions.
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more